Hormonal
Semaglutide (2.4 mg weekly) produces significant weight loss (mean -14.9%) in non-diabetic adults with obesity, but this efficacy is accompanied by a high incidence of mild-to-moderate gastrointestinal adverse events (nausea, vomiting, diarrhea) that often lead to treatment discontinuation.
Semaglutide 2.4mg weekly is highly effective for weight loss in non-diabetics, but expect significant gastrointestinal side effects like nausea and vomiting, especially during the first 16 weeks. These side effects are usually mild-to-moderate and transient, but they are the main reason people stop treatment. Medical supervision is crucial to manage these risks and monitor for rare but serious issues like pancreatitis.
a semaglutida 2·4 mg uma vez por semana alcançou uma diminuição superior e clinicamente significativa no peso corporal em comparação com o placebo... Os eventos adversos foram identificados em 87,6% dos pacientes em uso com semaglutida 2·4 mg e foram principalmente leves a moderados... Distúrbios gastrointestinais, como náusea, diarréia, constipação e vômitos foram os eventos adversos mais comuns decorrentes da semaglutida, eles foram tipicamente transitórios e de gravidade leve a moderada e diminuíram com o tempo.
Why this rating
Based on multiple Randomized Clinical Trials (RCTs) and meta-analyses included in the systematic review.
Source
O RISCO DE INTOXICAÇÃO PELO USO DO OZEMPIC (SEMAGLUTIDA) EM PACIENTES NÃO DIABÉTICOS
Rebecka Marques Gomes Sagratzki et al. · Brazilian Journal of Implantology and Health Sciences · 2023
DOI 10.36557/2674-8169.2023v5n4p1826-1837
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →